about
Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options.Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.Effects of anastrozole combined with Shuganjiangu decoction on osteoblast-like cell proliferation, differentiation and OPG/RANKL mRNA expression.Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trialEndocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole.
P2860
Q33754036-9D4CD115-DDB9-4967-9E49-AD66B8A2AD88Q33787731-B00BF067-500F-439E-972D-1B79FC6A0AD7Q36563142-8A491734-8757-4FA7-9947-1C01B53615C5Q37532912-ED0970C0-966A-4AA8-AFB4-B97EE85A6345Q37712223-B4BFD817-73F1-4701-B313-C60409B9DD4AQ39185424-F5F3D641-05C2-484D-B039-1563C827AAD5Q41684442-8A5B7044-1CA4-4538-8A67-131983E7F779
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Aromatase inhibitors and bone loss.
@ast
Aromatase inhibitors and bone loss.
@en
type
label
Aromatase inhibitors and bone loss.
@ast
Aromatase inhibitors and bone loss.
@en
prefLabel
Aromatase inhibitors and bone loss.
@ast
Aromatase inhibitors and bone loss.
@en
P2860
P1433
P1476
Aromatase inhibitors and bone loss.
@en
P2093
Edith A Perez
Katherine Weilbaecher
P2860
P304
1029-39; discussion 1039-40, 1042, 1048
P577
2006-08-01T00:00:00Z